Supplements

Long-term use of dual orexin receptor antagonists improves subjective sleep outcomes in adults with chronic insomnia

A systematic review and meta-analysis of 6 randomized controlled trials with 3,546 participants found that DORAs (suvorexant, lemborexant, daridorexant) improved subjective sleep parameters at 6 and 12 months. Adverse events were similar to placebo at 6 months but higher at 12 months, with no significant difference in overall discontinuation due to adverse events, though higher doses increased discontinuation at 6 months.

Last updated: Aug 20, 2026•0 RCTs•1 Meta-analyses•📖 Read as article →

Evidence Score

Evidence Score47/100
Human RCT☆☆☆☆☆
Meta-analysis★★★☆☆
Mechanism★★★★★
Safety★★★★☆
Confidencelow

Study Evidence

Study 1. Long-term use of dual orexin receptor antagonists for the treatment of insomnia: a systematic review and meta-analysis.

observational

Araujo LMM, Sousa AD, Vieira CC, Abreu JPP, Conti CF, Silva MML, Oliveira MM · Arquivos de neuro-psiquiatria (2026)

Participants: N/A
Duration: 6-12 months
Intervention: Dual orexin receptor antagonists (suvorexant, lemborexant, daridorexant) used for at least 6 months
Outcome: Subjective sleep parameters (e.g., sleep latency, total sleep time), adverse events, treatment discontinuation
Effect Size: N/A
Population: Adults with chronic insomnia (primary insomnia)

Result:

PubMed: 42595319DOI: 10.1055/s-0046-1827049

Mechanism Graph

DORAs block orexin receptors in the brain, reducing wakefulness signaling
↓
This promotes sleep initiation and maintenance
↓
Sustained blockade over months leads to continued improvement in sleep parameters
↓
Result: Improved subjective sleep outcomes at 6 and 12 months with acceptable safety profile

Limitations

  • ⚠Only 6 RCTs included, limiting generalizability
  • ⚠Higher doses associated with increased discontinuation at 6 months, suggesting tolerability issues
  • ⚠Long-term safety beyond 12 months not assessed

Frequently Asked Questions

What are dual orexin receptor antagonists (DORAs)?▼

DORAs are medications that block orexin receptors in the brain, reducing wakefulness and helping treat insomnia. Examples include suvorexant, lemborexant, and daridorexant.

How long can DORAs be used for insomnia?▼

This meta-analysis supports use for at least 6 to 12 months, showing sustained improvements in sleep outcomes with acceptable safety, though higher doses may be less tolerated.

Are DORAs safe for long-term use?▼

Adverse events were similar to placebo at 6 months but higher at 12 months. Overall discontinuation due to adverse events was not significantly different, but higher doses increased discontinuation at 6 months.

Which DORAs were included in this study?▼

The study included FDA-approved DORAs: suvorexant, lemborexant, and daridorexant.

Products

Affiliate links coming soon. We only recommend products that match the doses and forms used in the cited research.

References

  1. 1.Araujo LMM, Sousa AD, Vieira CC, Abreu JPP, Conti CF, Silva MML, Oliveira MM. "Long-term use of dual orexin receptor antagonists for the treatment of insomnia: a systematic review and meta-analysis.." Arquivos de neuro-psiquiatria, 2026. PMID: 42595319 DOI: 10.1055/s-0046-1827049
Disclaimer: This content is for educational purposes only and is not medical advice. Evidence scores reflect the quality and quantity of available research, not clinical recommendations. Always consult a healthcare professional before starting any supplement or intervention.